Angela Dimango, MD
Pulmonary Disease · New York, NYNPI 1720165400
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,545 of the $8,046 with a category attached, or 93.8%. Insmed, Inc. accounts for 94.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $6,221 and has fallen 73.7% since, to $1,633 in 2025.
Across 16 payments — averaging $502.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$8K
- Boehringer Ingelheim$310
- GSK$83
- AstraZeneca$56
Across 302 payments — averaging $769.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$105K
- Regeneron$75K
- Mannkind Corporation$25K
- Vertex$23K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$7,54594%
- Food & beverage$4566%
- Education$451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 6 | $7,597 |
| Boehringer Ingelheim | 3 | $310 |
| GSK | 4 | $83 |
| AstraZeneca | 3 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$3,018
How this compares
$8,046 in reported general payments places this provider in the 80th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 21 | $392,400 |
| Pirfenidone | 54 | $280,052 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 160 | $137,911 |
| Breo ElliptaFluticasone/Vilanterol | 122 | $71,931 |
| Dupixent PenDupilumab | 20 | $69,234 |
| NucalaMepolizumab | 11 | $45,674 |
| Dupixent SyringeDupilumab | 12 | $44,397 |
| Spiriva RespimatTiotropium Bromide | 43 | $38,499 |
| Incruse ElliptaUmeclidinium Bromide | 80 | $36,107 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $29,813 |
| Spiriva HandihalerTiotropium Bromide | 21 | $19,381 |
| Arnuity ElliptaFluticasone Furoate | 71 | $18,337 |
| EliquisApixaban | 16 | $15,307 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $14,796 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $310 | $436,22375 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $83 | $339,772505 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $56 | $29,25262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.